News Agency
The Times

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

  • Written by PR Newswire

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeutic signals in solid tumors, and good safety...

Read more: China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion